<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR47">
 <label>47.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Korthuis</surname>
    <given-names>PT</given-names>
   </name>
   <name>
    <surname>Lum</surname>
    <given-names>PJ</given-names>
   </name>
   <name>
    <surname>Vergara-Rodriguez</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Ahamad</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Wood</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Kunkel</surname>
    <given-names>LE</given-names>
   </name>
   <name>
    <surname>Oden</surname>
    <given-names>NL</given-names>
   </name>
   <name>
    <surname>Lindblad</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Sorensen</surname>
    <given-names>JL</given-names>
   </name>
   <name>
    <surname>Arenas</surname>
    <given-names>V</given-names>
   </name>
  </person-group>
  <article-title>Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial</article-title>
  <source>Addiction</source>
  <year>2017</year>
  <volume>112</volume>
  <fpage>1036</fpage>
  <lpage>1044</lpage>
  <pub-id pub-id-type="doi">10.1111/add.13753</pub-id>
  <?supplied-pmid 28061017?>
  <pub-id pub-id-type="pmid">28061017</pub-id>
 </element-citation>
</ref>
